LINC02352

Across TCGA pan-cancer cohorts, LINC02352 RNA differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of LINC02352’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where LINC02352 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LINC02352 is over-expressed in tumor, although a few such as BRCA and LUSC show the opposite, repressed pattern.

LIHC, BRCA, and LUSC are the cancer types where LINC02352 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LINC02352 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	All	+0.537	<.001	8	view →
BRCA	All	II,III,IV	−0.685	<.001	6	view →
LUSC	Male	All	−0.383	<.001	6	view →
CHOL	All	All	+0.934	<.001	3	view →
LUAD	All	III,IV	−0.373	.011	3	view →
BLCA	Male	IV	−0.622	.005	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

LINC02352–LIHC

Open the LIHC breakdown →